Next generation of multispecific antibody engineering

2023/12/08 by Dániel Kéri, Matt Walker, Isha Singh +2 · 1 voice · 1 citation
Medicine · Biochemistry, Genetics and Molecular Biology · #Monoclonal and Polyclonal Antibodies Research #Transgenic Plants and Applications #Protein purification and stability

paper · pdf · doi:10.1093/abt/tbad027

openalex publication_date 2023/12/08 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/29

Abstract

Multispecific antibodies recognize two or more epitopes located on the same or distinct targets. This added capability through protein design allows these man-made molecules to address unmet medical needs that are no longer possible with single targeting such as with monoclonal antibodies or cytokines alone. However, the approach to the development of these multispecific molecules has been met with numerous road bumps, which suggests that a new workflow for multispecific molecules is required. The investigation of the molecular basis that mediates the successful assembly of the building blocks into non-native quaternary structures will lead to the writing of a playbook for multispecifics. This is a must do if we are to design workflows that we can control and in turn predict success. Here, we reflect on the current state-of-the-art of therapeutic biologics and look at the building blocks, in terms of proteins, and tools that can be used to build the foundations of such a next-generation workflow.

Citations

• Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies
• Abundancia relativa y distribución de aves marinas frente a la costa peruana y su relación con la anchoveta. Crucero BIC Humboldt 9803-05 de Tumbes a Tacna
• De novoprotein design, a retrospective
• Biological structure and function emerge from scaling unsupervised learning to 250 million protein sequences
• Highly accurate protein structure prediction with AlphaFold
• Accurate prediction of protein structures and interactions using a three-track neural network
• Why 90% of clinical drug development fails and how to improve it?

Cited by

• Antibody-drug conjugates as multimodal therapies against hard-to-treat cancers

Discussions

• This article, published last year, has already been cited 30 times, and downloaded over 21,000 times! Many thanks to the authors from Gilead! #AntibodyEngineering #MultiSpecific doi.org/10.1093/abt [bsky, 0 points, 0 comments]